Hikma Pharmaceuticals PLC ADR (HKMPY PINK) stock market data APIs
$53.2946
0.63(1.2%)
as of March 14, 2025
Hikma Pharmaceuticals PLC ADR Financial Data Overview
Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment provides generic injectable products primarily for use in hospitals. The Generics segment offers oral and other non-injectable generic products for the retail market. The Branded segment offers branded generics and in-licensed products to retail and hospital markets. The company provides its products in various therapeutic areas, including respiratory, oncology, and pain management. It also offers its products in solid, semi-solid, liquid, and injectable final dosage forms. The company operates in the United Kingdom, rest of Europe, North America, the Middle East, North Africa, and internationally. Hikma Pharmaceuticals PLC was founded in 1978 and is headquartered in London, the United Kingdom.
Prev. Close
52.6641
Open
53.2946
High
53.2946
Low
52.6641
52 wk Range
44.1995-59.26
Market Cap
5 806 M
P/E Ratio
30.7824
Shares Outstanding
111 M
Revenue
3 127 M
Dividends (Yield)
0.0306
Beta
0.451
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Hikma Pharmaceuticals PLC ADR data using free add-ons & libraries
Get Hikma Pharmaceuticals PLC ADR Fundamental Data
Hikma Pharmaceuticals PLC ADR Fundamental data includes:
- Net Revenue: 3 127 M
- EBITDA: 766 M
- Earnings Per Share: 1
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-02-20
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Hikma Pharmaceuticals PLC ADR News
New
AXSM Settles Sunosi Patent Litigation With Hikma Pharmaceuticals
Axsome Therapeutics AXSM announced that it has entered into a settlement agreement with Hikma Pharmaceuticals related to patents for its narcolepsy drug, Sunosi (solriamfetol). The settlement agreeme...
Hikma Pharmaceuticals Full Year 2024 Earnings: Revenues Beat Expectations, EPS Lags
Hikma Pharmaceuticals (LON:HIK) Full Year 2024 Results Key Financial Results Revenue: US$3.13b (up 8.8% from FY 2023). Net income: US$359.0m (up 89% from FY 2023). Profit margin: 12% (up from 6.6% i...
Hikma Pharmaceuticals PLC (HKMPF) (Q4 2024) Earnings Call Highlights: Surpassing Revenue ...
Release Date: February 26, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Hikma Pharmaceuticals PLC (HKMPF) achieved a gro...
Trending tickers: Nvidia, Tesla, Super Micro, AB InBev and BP
Nvidia (NVDA) After closing Tuesday's session nearly 3% in the red, Nvidia (NVDA) shares were up 1.5% in pre-market trading on Wednesday, ahead of the release of the chipmaker's highly anticipated ea...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
